PACS Group's stock soared 25.36% during intraday trading on Tuesday, marking a significant surge in the healthcare company's share price.

The dramatic rise follows the company's release of first-quarter 2026 financial results that substantially exceeded analyst expectations. PACS Group reported quarterly earnings of $0.50 per share, beating the consensus estimate of $0.40, while revenue reached $1.42 billion, surpassing estimates of $1.36 billion and representing an 11.2% year-over-year increase.

Investor sentiment was further boosted by the company's decision to raise its full-year 2026 adjusted EBITDA guidance to $605-$625 million from the previous range of $555-$575 million. Additionally, the board approved a new $250 million share repurchase authorization. Company leadership credited the strong quarterly performance to improved occupancy rates, increased skilled mix, and benefits from incentive programs at both newer and existing facilities.